How to Sell Peptides in 2026: The Complete Guide

Selling peptides is not one business. It is two businesses that look identical from the outside and are completely different underneath. Lane one is research use only: you sell lyophilized compounds to a research audience, with no dosing guidance, no human-use claims, and no implied therapeutic benefit. Lane two is clinical: a licensed prescriber evaluates a patient, writes a prescription, and a 503A compounding pharmacy or 503B outsourcing facility fills it. Choose the wrong lane, or try to straddle both, and you lose your merchant account, your ad account, or worse.

Everything else in this guide sits on top of that decision. The website, the processor, the creative, the fulfillment partner, the email flows: all of it changes depending on which lane you are in. So before you spend a dollar on inventory, decide what you are actually selling and to whom.

lane 1: research use only (RUO)

The RUO model sells peptides as laboratory reagents. That means the product is labeled clearly as not for human consumption, the site carries no dosing protocols, no before-and-after photos, no testimonials describing weight loss or healing, and no language that would make a reasonable person believe the product is a drug. The FDA and FTC both police this. The failure mode is not subtle: a site sells BPC-157 with a page titled how to inject BPC-157 for tendon repair, and the RUO disclaimer in the footer becomes meaningless. Intended use is determined by your whole presentation, not your footer.

Done correctly, RUO is a genuinely viable ecommerce business. Gross margins run 75 to 88 percent. You do not need prescribers, patient intake, or state-by-state telehealth licensure. What you do need is disciplined copy, third-party certificates of analysis (COA) for every lot, an age gate, a buyer attestation at checkout, and a lawyer who has actually read your site. Budget for that review. It is the cheapest insurance in this category.

lane 2: clinical and compounded

The clinical lane is where med spas and telehealth brands live. A licensed provider does a real evaluation, orders labs where appropriate, writes a patient-specific prescription, and a 503A pharmacy compounds it. This lane can make real medical claims within the bounds of the prescriber relationship, and it can charge four to ten times what an RUO vial sells for. It is also heavier: corporate practice of medicine rules in most states mean the clinical entity has to be owned by licensed providers, with a management services organization (MSO) handling marketing, tech, and admin under a management services agreement.

If you already own a med spa, you are most of the way there. You have the prescriber, the license, the patient relationships. What you are missing is the ecommerce layer: an online store your existing patients can reorder from, a compliant intake, and a way to acquire new patients at a cost that works. That is the highest-leverage version of this whole business.

the stack you actually need

Regardless of lane, the build is the same seven pieces. Most people get four of them right and then wonder why the launch stalls.

1. 1.Entity and legal: LLC or PC depending on lane, terms of sale, RUO attestation or patient consent, privacy policy, and an attorney review of your actual live site copy, not a template.
2. 2.Sourcing: a manufacturer with third-party COAs per lot, HPLC and mass spec results, and documented purity above 98 percent. Get samples independently tested before you commit to a purchase order.
3. 3.Payment processing: a high-risk merchant account underwritten specifically for your product category. This is the single most common launch blocker.
4. 4.Store: fast, clean, conversion-built. Product pages that sell without making claims you cannot make. Subscription option for reorders.
5. 5.Traffic: Meta ads as the primary channel, with creative built to pass review on the first pass, plus organic and email as the compounding layer.
6. 6.Fulfillment: a 3PL that understands temperature control, lot tracking, and the labeling requirements for your lane.
7. 7.Retention: email and SMS flows. In this category the second order is where the business actually gets profitable.

payment processing is what kills most launches

Stripe, Shopify Payments, PayPal, and Square all prohibit this category in their acceptable use policies. People try anyway, code the product as supplements, get 30 to 60 days of processing, and then get a freeze with a 90 to 180 day hold on the balance. That is not a hypothetical. It is the most common way a peptide brand dies in month two.

The correct move is a high-risk acquirer that underwrites you honestly for what you sell. Expect the following economics:

• —Discount rate of roughly 3.5 to 5.5 percent plus 25 to 35 cents per transaction, versus 2.9 percent on a standard gateway.
• —A rolling reserve of 5 to 10 percent held for 180 days, released on a rolling basis. Model this in your cash flow or you will run out of working capital while profitable on paper.
• —Underwriting that wants your site live, your policies posted, your COAs visible, and your refund terms clear before they approve.
• —Chargeback discipline. Card networks start monitoring programs around the 0.9 to 1 percent mark. Descriptor clarity, a working support line, and fast refunds keep you well under it.
• —A backup processor. Always. Single-processor brands are one underwriting review away from zero revenue.

how you actually get traffic

Meta is the volume channel. Google restricts most of this category, TikTok is worse, and organic takes six months to matter. So the question becomes how to run Meta ads that pass review, convert, and do not put your business manager at risk. The answer is boring and it works: no personal attributes language, no implied diagnosis, no before-and-after imagery, no dramatic transformation claims, no promises of specific outcomes. You sell the category, the credibility, and the experience. You let the landing page and the intake do the qualifying.

That constraint sounds like a handicap. It is not. Our top-performing accounts in this space run inside those rules and still print. On AC-NEXTGEN, top creatives sit between 7.5 and 16 ROAS, and one single ad returned $53,269 on $6,049 in spend. On Goodscience, one creative returned $33,225 on $8,664. On WayyLess, $4.3M in ad spend produced $19.1M in revenue at a 4.45 blended ROAS. None of that required a claim we could not defend.

The mechanical part matters as much as the creative. Verified domain, aged business manager, proper CAPI implementation with server-side events, deduplication set up correctly, and a landing page whose claims match the ad exactly. Mismatch between ad and landing page is the most common trigger for a manual review that goes badly.

pricing and margin, in real numbers

RUO vials land somewhere between $8 and $22 depending on compound, volume, and lot size. Retail typically sits at $45 to $95. That is a 75 to 88 percent gross margin, which sounds enormous until you subtract a 4.5 percent processing rate, $6 to $9 of fulfillment, and a customer acquisition cost that in a competitive month can be $45 to $70. Now your first order is roughly break-even and the business is entirely built on the second and third order.

The clinical lane is different math. A month of compounded product costs the clinic $150 to $260 and retails at $299 to $549, so gross margin is thinner in percentage terms and much larger in dollar terms. Because it is a recurring monthly refill, lifetime value is usually four to eight months. That gives you a far bigger acquisition budget, which is exactly why med spas that add an online reorder channel scale faster than pure RUO stores.

the mistakes we see over and over

• —Straddling the lanes. Selling RUO product while running lifestyle creative that implies human use. This is how you lose everything at once.
• —Launching on a mainstream processor to save 2 points. You will pay it back with a 180 day hold.
• —No COAs, or COAs from the manufacturer instead of an independent lab. Buyers in this category check.
• —One SKU. You need a cart-building assortment plus a reorder mechanism, or your AOV never clears your CAC.
• —Zero email infrastructure at launch. Abandoned cart, post-purchase, and reorder flows commonly account for 20 to 30 percent of revenue in this category.
• —Treating the disclaimer as the compliance strategy. Compliance is the whole presentation.

a realistic launch timeline

1. 1.Days 1 to 3: lane decision, entity, and attorney engagement. Start high-risk merchant underwriting immediately since it is the long pole.
2. 2.Days 3 to 7: sourcing conversations, sample orders sent for independent testing, 3PL selected, store built and populated.
3. 3.Days 7 to 10: policies, COA hosting, intake or attestation flow, tracking and CAPI, email flows loaded.
4. 4.Days 10 to 14: processor approved, creative produced, campaigns structured, soft launch to a small budget.
5. 5.Weeks 3 to 6: scale on what works, kill what does not, and get the reorder flow tight before you push spend hard.

the brands that win this category are not the ones with the cleverest ads. they are the ones whose compliance, processing, and fulfillment were boring enough to survive the scale.

One last thing. Nothing here is legal or medical advice. Peptide regulation moves, state law varies, and the FDA position on specific compounds changes. Retain a healthcare regulatory attorney before you sell anything, and re-review your site whenever you add a SKU or change your claims.